Patient considerations in the management of toe onychomycosis – Role of efinaconazole

Charlotte E. LaSenna, Antonella Tosti

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Onychomycosis is a difficult diagnosis to manage and treatment is sometimes avoided, as this diagnosis is often wrongly perceived as a cosmetic problem. However, onychomycosis has a negative impact on patients’ quality of life, affecting social interaction, psychological well-being, and physical activities. Onychomycosis is also a risk factor for patients with diabetes, with proven increased rates of cellulitis, gangrene, and foot ulcers. Treatments are only mild to moderately effective, and rates of relapse and reinfection are high. Oral treatments require laboratory monitoring due to risk of hepatotoxicity and may be contraindicated in some patients due to risk of drug–drug interactions. Topical treatments require prolonged application and are not very effective. Efinaconazole 10% solution is a new topical triazole treatment for mild to moderate distal subungual onychomycosis, with good efficacy and without the need for debridement of nails. In onychomycosis of the toenails, efinaconazole 10% solution is documented to have a statistically significant, positive impact on patient satisfaction and quality of life.

Original languageEnglish (US)
Pages (from-to)887-891
Number of pages5
JournalPatient Preference and Adherence
Volume9
DOIs
StatePublished - Jun 30 2015

Fingerprint

Onychomycosis
Toes
quality of life
management
Nails
cosmetics
relapse
interaction
chronic illness
Quality of Life
Foot Ulcer
Therapeutics
well-being
Triazoles
Cellulitis
Gangrene
monitoring
Debridement
Interpersonal Relations
Patient Satisfaction

Keywords

  • Antifungal
  • Dermatophyte
  • Fungus
  • Nail
  • Quality of life
  • Treatment

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Medicine (miscellaneous)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Patient considerations in the management of toe onychomycosis – Role of efinaconazole. / LaSenna, Charlotte E.; Tosti, Antonella.

In: Patient Preference and Adherence, Vol. 9, 30.06.2015, p. 887-891.

Research output: Contribution to journalArticle

@article{cde78de0531c4c8f99e0b54f2131cbb0,
title = "Patient considerations in the management of toe onychomycosis – Role of efinaconazole",
abstract = "Onychomycosis is a difficult diagnosis to manage and treatment is sometimes avoided, as this diagnosis is often wrongly perceived as a cosmetic problem. However, onychomycosis has a negative impact on patients’ quality of life, affecting social interaction, psychological well-being, and physical activities. Onychomycosis is also a risk factor for patients with diabetes, with proven increased rates of cellulitis, gangrene, and foot ulcers. Treatments are only mild to moderately effective, and rates of relapse and reinfection are high. Oral treatments require laboratory monitoring due to risk of hepatotoxicity and may be contraindicated in some patients due to risk of drug–drug interactions. Topical treatments require prolonged application and are not very effective. Efinaconazole 10{\%} solution is a new topical triazole treatment for mild to moderate distal subungual onychomycosis, with good efficacy and without the need for debridement of nails. In onychomycosis of the toenails, efinaconazole 10{\%} solution is documented to have a statistically significant, positive impact on patient satisfaction and quality of life.",
keywords = "Antifungal, Dermatophyte, Fungus, Nail, Quality of life, Treatment",
author = "LaSenna, {Charlotte E.} and Antonella Tosti",
year = "2015",
month = "6",
day = "30",
doi = "10.2147/PPA.S72701",
language = "English (US)",
volume = "9",
pages = "887--891",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Patient considerations in the management of toe onychomycosis – Role of efinaconazole

AU - LaSenna, Charlotte E.

AU - Tosti, Antonella

PY - 2015/6/30

Y1 - 2015/6/30

N2 - Onychomycosis is a difficult diagnosis to manage and treatment is sometimes avoided, as this diagnosis is often wrongly perceived as a cosmetic problem. However, onychomycosis has a negative impact on patients’ quality of life, affecting social interaction, psychological well-being, and physical activities. Onychomycosis is also a risk factor for patients with diabetes, with proven increased rates of cellulitis, gangrene, and foot ulcers. Treatments are only mild to moderately effective, and rates of relapse and reinfection are high. Oral treatments require laboratory monitoring due to risk of hepatotoxicity and may be contraindicated in some patients due to risk of drug–drug interactions. Topical treatments require prolonged application and are not very effective. Efinaconazole 10% solution is a new topical triazole treatment for mild to moderate distal subungual onychomycosis, with good efficacy and without the need for debridement of nails. In onychomycosis of the toenails, efinaconazole 10% solution is documented to have a statistically significant, positive impact on patient satisfaction and quality of life.

AB - Onychomycosis is a difficult diagnosis to manage and treatment is sometimes avoided, as this diagnosis is often wrongly perceived as a cosmetic problem. However, onychomycosis has a negative impact on patients’ quality of life, affecting social interaction, psychological well-being, and physical activities. Onychomycosis is also a risk factor for patients with diabetes, with proven increased rates of cellulitis, gangrene, and foot ulcers. Treatments are only mild to moderately effective, and rates of relapse and reinfection are high. Oral treatments require laboratory monitoring due to risk of hepatotoxicity and may be contraindicated in some patients due to risk of drug–drug interactions. Topical treatments require prolonged application and are not very effective. Efinaconazole 10% solution is a new topical triazole treatment for mild to moderate distal subungual onychomycosis, with good efficacy and without the need for debridement of nails. In onychomycosis of the toenails, efinaconazole 10% solution is documented to have a statistically significant, positive impact on patient satisfaction and quality of life.

KW - Antifungal

KW - Dermatophyte

KW - Fungus

KW - Nail

KW - Quality of life

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84936937643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936937643&partnerID=8YFLogxK

U2 - 10.2147/PPA.S72701

DO - 10.2147/PPA.S72701

M3 - Article

AN - SCOPUS:84936937643

VL - 9

SP - 887

EP - 891

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -